HomeEX1 • ASX
add
Tryptamine Therapeutics Ltd
Previous close
$0.028
Year range
$0.020 - $0.050
Market cap
1.93M AUD
P/E ratio
-
Dividend yield
-
Primary exchange
ASX
Market news
Financials
Income Statement
Revenue
Net income
(AUD) | Dec 2023info | Y/Y change |
---|---|---|
Revenue | 18.30K | -98.37% |
Operating expense | 690.33K | -69.35% |
Net income | -805.30K | 63.58% |
Net profit margin | -4.40K | -2,134.79% |
Earnings per share | — | — |
EBITDA | -517.09K | 72.18% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
(AUD) | Dec 2023info | Y/Y change |
---|---|---|
Cash and short-term investments | 2.61M | 54.78% |
Total assets | 3.08M | -56.68% |
Total liabilities | 367.88K | -86.50% |
Total equity | 2.71M | — |
Shares outstanding | 175.77M | — |
Price to book | 1.38 | — |
Return on assets | -65.60% | — |
Return on capital | -74.49% | — |
Cash Flow
Net change in cash
(AUD) | Dec 2023info | Y/Y change |
---|---|---|
Net income | -805.30K | 63.58% |
Cash from operations | 906.76K | 346.47% |
Cash from investing | 347.95K | 554.22% |
Cash from financing | -772.36K | 32.09% |
Net change in cash | 482.38K | 130.51% |
Free cash flow | -422.83K | 71.08% |
About
Founded
2013
Website
Employees
50